ARCHIVES

Phase III Afatinib Trial Met Primary Endpoint In Stage IIIb or IV Cancer with EGFR Mutation

This article is from The Cancer Letter archive.

Vol. 35 No. 6 | June 29, 2012

Download PDF Visit The Full Archive

Related Articles

Science Fellowships Available; Grants For Former Soviet Scientists

August 16, 1996

NCI Places Hold On Genentech Drug Trials, Citing Disagreement Over Intellectual Property Provisions.

March 12, 2010

Recombinant TSH Avoids Need To Stop Replacement Therapy

January 27, 2006

NCI Publishes FOA For Trials Network Program

July 27, 2012

Tasigna Shows Benefit Over Gleevec In Phase III Study for Ph+ CML In Chronic Phase

December 31, 2010

Research teams link response to Iressa to mutations in EGF receptor.

April 30, 2004